Progression and expansion of ALK inhibitors against NSCLC: A dual target approach

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Anaplastic Lymphoma Kinase (ALK) is crucial in non-small cell lung cancer (NSCLC) progression.
• Current ALK inhibitors face resistance, leading to treatment failure.
• Targeting ALK alongside other oncogenic pathways presents a promising therapeutic strategy.

Purpose of the Study:

• To review ALK's role and its synergy with other anti-tumor targets.
• To summarize recent advancements in ALK dual inhibitor synthesis.
• To provide insights for developing novel ALK-based dual inhibitors.

Main Methods:

• Literature review of ALK inhibitors and dual inhibitor development.
• Analysis of design concepts and structure-activity relationships (SARs).
• Evaluation of preclinical and clinical data, including in silico studies.

Main Results:

• ALK rearrangements drive NSCLC, with existing inhibitors showing limitations due to resistance.
• Dual inhibitors targeting ALK and other pathways (e.g., ROS1, c-MET, EGFR) are emerging.
• These inhibitors aim to enhance efficacy and overcome resistance mechanisms.

Conclusions:

• Dual ALK inhibitors represent a significant advancement in NSCLC treatment.
• Further research into their design, SARs, and clinical data is essential.
• Novel ALK-based dual inhibitors hold potential for patients with complex molecular profiles.